A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

Removille, Nathalie; Origer, Alain; Couffignal, Sophie; Vaillant, Michel; Schmit, Jean-Claude; Lair, Marie-Lise
January 2011
BMC Public Health;2011 Supplement 4, Vol. 11 Issue Suppl 4, p351
Academic Journal
Background: In Luxembourg, viral hepatitis and HIV infection data in problem drug users (PDUs) are primarily based on self-reporting. Our study aimed to determine the prevalence of HAV, HBV, HCV and HIV infections in ever injecting (IDUs) and non-injecting drug users (nIDUs) including inherent risk factors analysis for IDUs. Secondary objectives were immunisation against HAV and HBV, referral to care and treatment facilities as well as reduction in risk behaviour. Methods: A nationwide, cross-sectional multi-site survey, involving 5 in-, 8 out-treatment and 2 prison centres, included both an assisted questionnaire (n = 368) and serological detection of HIV and Hepatitis A, B, C (n = 334). A response rate of 31% resulted in the participation of 310 IDUs and 58 nIDUs. Risk factors such as drug use, sexual behaviour, imprisonment, protection and health knowledge (HAV, HBV status and immunisations, HCV, HIV), piercing/tattoo and use of social and medical services were studied by means of chi2 and logistic models. Results: Seroprevalence results for IDUs were 81.3% (218/268, 95%CI=[76.6; 86.0]) for HCV, 29.1% (74/254, 95%CI= [25.5;34.7 ]) for HBV (acute/chronic infection or past cured infection), 2.5% (5/202, 95%CI=[0.3; 4.6]) for HIV-1 and 57.1% (108/189, 95%CI=[50.0; 64.1]) for HAV (cured infections or past vaccinations). Seroprevalence results for nIDUs were 19.1% (9/47, 95%CI=[7.9;30.3]) for HCV, 8.9% (4/45, 95%CI=[0.6;17.2]) for HBV (acute/chronic infection or past cured infection), 4.8% (2/42, 95%CI=[-1.7;11.3]) for HIV-1 and 65.9% (27/41, 95%CI=[51.4;80.4]) for HAV. Prisoners showed the highest rates for all infections. Age, imprisonment and setting of recruitment were statistically associated with HCV seropositivity. Age, speedball career and nationality were significantly associated with HBV seropositivity. Only 56% of the participants in outpatient centres collected their serology results and 43 doses of vaccine against HAV and/or HBV were administered. Conclusions: Despite the existing national risk-reduction strategies implemented since 1993, high prevalence of HCV and HBV infections in injecting drug users is observed. Our study showed that implementing risk-prevention strategies, including immunisation remains difficult with PDUs. Improvement should be looked for by the provision of field healthcare structures providing tests with immediate results, advice, immunisation or treatment if appropriate.


Related Articles

  • DRUG PARAPHERNALIA LAWS AND INJECTION-RELATED INFECTIOUS DISEASE RISK AMONG DRUG INJECTORS. Bluthenthal, Ricky N.; Kral, Alex H.; Erringer, Elizabeth A.; Edlin, Brian R. // Journal of Drug Issues;Winter99, Vol. 29 Issue 1, p1 

    The article reports on the injection drug users (IDUs) and related diseases among drug injectors. The IDUs are considered to be at major risk for infection with human immunodeficiency virus (HIV) and other related diseases. These diseases include hepatitis B virus and hepatitis C virus. The...

  • Reducing therapeutic injection overuse through patients-prescribers Interaction Group Discussions in Kinondoni District, Dar es Salaam, Tanzania. Massele, Amos Y.; Mashalla, Yohana J.; Kayombo, Edmund J.; Waiselage, Julius D.; Mwamba, Natu E.; Kaniki, Issessanda // Tanzania Journal of Health Research;Feb2011, Vol. 13 Issue 1, p87 

    Inappropriately prescription of injections has been reported in developing and developed countries. Previous studies in Tanzania showed that over 70% of patients attending out-patient clinics at private dispensaries received at least one injection per consultation, a value higher than WHO...

  • Estimating the Burden of Disease from Unsafe Injections in India: A Cost-benefit Assessment of the Auto-disable Syringe in a Country with Low Blood-borne Virus Prevalence. Reid, Savanna // Indian Journal of Community Medicine;Apr-Jun2012, Vol. 37 Issue 2, p89 

    Background: Unsafe medical injections are a prevalent risk factor for viral hepatitis and HIV in India. Objectives: This review undertakes a cost-benefit assessment of the auto-disable syringe, now being introduced to prevent the spread of hepatitis B virus, hepatitis C virus, and human...

  • Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. Adewole, Olanisun Olufemi; Anteyi, Emmanuel; Ajuwon, Zaccheus; Wada, Ibrahim; Elegba, Funmilayo; Ahmed, Patience; Betiku, Yewande; Okpe, Andy; Eze, Stella; Ogbeche, Tomi; Erhabor, Greg Efosa // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p369 

    Introduction: We set out to determine the seroprevalence of hepatitis B and hepatitis C viruses among human immunodeficiency virus infected individuals and its impact on pattern of presentation. Methodology: A serological study for hepatitis B and hepatitis C viruses was performed on 260...

  • Outcome of Intravenous Immunoglobulin-Transmitted HTLV-I, Hepatitis B, Hepatitis C, and HIV infections. Foroughipour, Mohsen; Jabbari Azad, Farahzad; Farid hosseini, Reza; Shirdel, Abbas; Reza Khalighi, Amir; Yousefzadeh, Hadis; Sadri, Homa; Moghiman, Toktam; Hekmatkhah, Hossein // Iranian Journal of Basic Medical Sciences;Mar2013, Vol. 16 Issue 3, p228 

    Objective(s): Since each unit of Intravenous Immunoglobulin (IVIG) is obtained from different blood donors, blood-borne viral diseases is of high importance. We aimed at investigating the prevalence of various viral infections: Human T-cell Lymphotropic Virus Type 1 (HTLV-I), Hepatitis B (HBV),...

  • Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1--Infected Individuals. Gandhi, Rajesh T.; Wurcel, Alysse; Hang Lee; McGovern, Barbara; Boczanowski, Melinda; Gerwin, Roslyn; Corcoran, Colleen P.; Szczepiorkowski, Zbingniew; Toner, Sarah; Cohen, Daniel E.; Sax, Paul E.; Ukomadu, Chinweike // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1602 

    We screened 651 human immunodeficiency virus (HIV)-1-infected subjects for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B surface antigen (anti-HBs). Of a total of 387 subjects who tested negative for both HBsAg and anti-HBs, 142 underwent further testing for isolated presence...

  • Scotland: Executive proposes mandatory HIV testing for criminal suspects.  // HIV/AIDS Policy & Law Review;Aug2005, Vol. 10 Issue 2, p36 

    This article reports that in February 2005, the Scottish Executive released legislative proposals that would allow police officers, health care workers, victims of crime and other persons at risk of infection to apply for compulsory HIV, hepatitis B and hepatitis C testing of criminal suspects....

  • International Adoption: Infectious Diseases Issues. Miller, Laurie C. // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, p286 

    Nearly 220,000 children have been adopted from other countries by American parents since 1986. Approximately 65,000 children have arrived from China and Russia, mostly in the past 6 years. Most of these children reside in orphanages before adoption, where they may experience malnutrition,...

  • Hepatitis B, hepatitis C and HIV co-infection at an antiretroviral centre in Delhi. Raizada, A.; Dwivedi, S.; Bhattacharya, S. // Tropical Doctor;Jul2011, Vol. 41 Issue 3, p154 

    With an estimated 5.7 million people living with HIV/AIDS, India has the highest HIV/AIDS prevalence in the world, according to UNAIDS. Due to similar routes of transmission, co-infection of HIV with hepatitis B and hepatitis C viruses is a common event with significant clinical implications....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics